Cambridge Investment Research Advisors, Inc. Virpax Pharmaceuticals, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$27.1 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.67 - $1.15 $268 - $459	-400 Reduced 2.43%	16,070 $13,000
Q4 2022 Feb 08, 2023	SELL	$0.62 - $12.0 $217 - $4,200	-350 Reduced 2.08%	16,470 $10,000
Q2 2022 Jul 13, 2022	SELL	$1.22 - $2.25 $427 - $787	-350 Reduced 2.04%	16,820 $28,000
Q1 2022 May 12, 2022	SELL	$1.86 - $3.61 $1,116 - $2,166	-600 Reduced 3.38%	17,170 $38,000
Q4 2021 Feb 03, 2022	SELL	$3.19 - $4.89 $5,263 - $8,068	-1,650 Reduced 8.5%	17,770 $60,000
Q3 2021 Nov 02, 2021	BUY	$4.14 - $22.9 $80,398 - $444,718	19,420 New	19,420 $93,000

Others Institutions Holding VRPX

# of Institutions

Shares Held

Call Options Held

Put Options Held

Parallel Advisors, LLC

1
Shares

$0
0.0% of portfolio

View Full List

About Virpax Pharmaceuticals, Inc.

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.97M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

More about VRPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account